Daxxify Injection, Powder, Lyophilized, For Solution
NDC 72960-112
Product Information
Daxxify (botulinum toxin type a) is a BLA-approved product labeled by Revance Therapeutics, Inc.. This medication is typically used as a acetylcholine release inhibitor [epc]. It is supplied as a injection, powder, lyophilized, for solution for intramuscular administration. This product entry covers the primary NDC 72960-112 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 72960-112?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BOTULINUM TOXIN TYPE A (UNII: E211KPY694)
- BOTULINUM TOXIN TYPE A (UNII: E211KPY694) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HISTIDINE (UNII: 4QD397987E)
- TREHALOSE DIHYDRATE (UNII: 7YIN7J07X4)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2612454 - daxibotulinumtoxinA-lanm 100 UNT Injection
- RxCUI: 2612456 - Daxxify 100 UNT Injection
- RxCUI: 2612456 - daxibotulinumtoxinA-lanm 100 UNT Injection [Daxxify]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.